Shortfall In Rebates Could Stymie UK Generics Industry’s Call For Exemptions Under New Pricing Scheme
Executive Summary
The UK’s generics and biosimilars industry body, the BGMA, has set out what it wants from the new drug pricing scheme due to start up in January 2024. But a key request – exempting some branded generics and biosimilars from rebates - would leave a hole in the government’s finances.